A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Inclusion Criteria: Participants with confirmed unresectable HCC Participants with Lung dose threshold for Yttrium 90 glass microspheres of 30 Gy (equal or less than 30 Gy per treatment for glass) and an estimated Future liver remnant volume (FLRV) ≥ 30% of whole liver volume Participants with no evidence of extrahepatic disease on any available imaging Participants with one or more measurable lesions, unilobar disease for participants with segmental or right anterior/posterior portal vein invasion (Vp1/Vp2) and eligible for Yttrium 90 glass microspheres TARE. Participants having Child-Pugh score class A. Participants having ECOG performance status of 0 or 1 at enrollment Adequate organ and marrow function Exclusion Criteria: Disease amenable to curative surgery or transplantation or curative ablation. Participants co-infected with HBV and HDV Any history of nephrotic or nephritic syndrome. Clinically significant (eg, active) cardiovascular disease Participants with uncontrolled hypertension History of hepatic encephalopathy Known hereditary predisposition to bleeding or thrombosis; any prior or current evidence of bleeding diathesis. Receipt of more than 1 prior embolization (TACE or TARE) treatment/procedure Participant has received any prior anticancer systemic therapy for unresectable HCC. History of arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to enrollment. History of abdominal fistula or gastrointestinal (GI) perforation, non-healed gastric ulcer that is refractory to treatment, or active GI bleeding within 6 months prior to enrollment